镰状细胞病的基因治疗——有待偿还的债务。 - Suppr

Suppr

超能文献

Gene Therapy for Sickle Cell Disease-A Debt to Be Paid.

作者信息

Ozuah Philip O

机构信息

Albert Einstein College of Medicine and Montefiore Medicine, Bronx, New York.

出版信息

JAMA Pediatr. 2021 Jun 1;175(6):565-566. doi: 10.1001/jamapediatrics.2020.7147.

DOI:10.1001/jamapediatrics.2020.7147

PMID:33749705

Abstract

摘要

相似文献

Gene Therapy for Sickle Cell Disease-A Debt to Be Paid.

JAMA Pediatr. 2021 Jun 1;175(6):565-566. doi: 10.1001/jamapediatrics.2020.7147.

[Genetic conservation of sickle cell trait].

Ann Soc Belg Med Trop (1920). 1955 Dec 31;35(6):649-60.

Therapeutic strategies in Sickle Cell Anemia: The past present and future.

Life Sci. 2017 Jun 1;178:100-108. doi: 10.1016/j.lfs.2017.03.025. Epub 2017 Apr 20.

Genetic Therapies for Sickle Cell Disease.

Pediatr Clin North Am. 2018 Jun;65(3):465-480. doi: 10.1016/j.pcl.2018.01.008.

Acceptability of prenatal diagnosis by a sample of parents of sickle cell anemia patients in Cameroon (sub-Saharan Africa).

J Genet Couns. 2011 Oct;20(5):476-85. doi: 10.1007/s10897-011-9372-y. Epub 2011 May 21.

Gene Therapy in a Patient with Sickle Cell Disease.

N Engl J Med. 2017 May 25;376(21):2093-4. doi: 10.1056/NEJMc1704009.

Gene Therapy in a Patient with Sickle Cell Disease.

N Engl J Med. 2017 May 25;376(21):2094. doi: 10.1056/NEJMc1704009.

Bone marrow transplantation (BMT) and gene replacement therapy (GRT) in sickle cell anemia.

Niger J Med. 2008 Jul-Aug;17(3):251-6. doi: 10.4314/njm.v17i3.37390.

Rounding up sickle cells with gene therapy.

Sci Transl Med. 2017 Mar 15;9(381). doi: 10.1126/scitranslmed.aam9864.

Gene therapy in sickle cell disease: Possible utility and impact.

Cleve Clin J Med. 2020 Jan;87(1):28-29. doi: 10.3949/ccjm.87a.19124. Epub 2020 Jan 2.

引用本文的文献

Balancing benefits and burdens: a systematic review on ethical and social dimensions of gene and cell therapies for hereditary blood diseases.

BMC Med Ethics. 2025 Mar 14;26(1):36. doi: 10.1186/s12910-025-01188-3.

CRISPR technology in human diseases.

MedComm (2020). 2024 Jul 29;5(8):e672. doi: 10.1002/mco2.672. eCollection 2024 Aug.

Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women.

Expert Rev Hematol. 2024 Aug;17(8):493-504. doi: 10.1080/17474086.2024.2372320. Epub 2024 Jun 26.

Life after sickle cell disease, is it really uhuru?

Lancet Haematol. 2023 Dec;10(12):e946-e949. doi: 10.1016/S2352-3026(23)00306-X.

A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America.

Pharmacoecon Open. 2023 Mar;7(2):313-320. doi: 10.1007/s41669-023-00390-6. Epub 2023 Feb 11.

Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study.

PLoS One. 2022 Nov 29;17(11):e0278137. doi: 10.1371/journal.pone.0278137. eCollection 2022.

Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance.

Blood Adv. 2023 Feb 14;7(3):365-374. doi: 10.1182/bloodadvances.2021006281.

A landscape analysis and discussion of value of gene therapies for sickle cell disease.

Expert Rev Pharmacoecon Outcomes Res. 2022 Sep;22(6):891-911. doi: 10.1080/14737167.2022.2060823. Epub 2022 Apr 18.

Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.

Mol Ther. 2021 Nov 3;29(11):3163-3178. doi: 10.1016/j.ymthe.2021.10.002. Epub 2021 Oct 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Gene Therapy for Sickle Cell Disease-A Debt to Be Paid.

JAMA Pediatr. 2021 Jun 1;175(6):565-566. doi: 10.1001/jamapediatrics.2020.7147.

[Genetic conservation of sickle cell trait].

Ann Soc Belg Med Trop (1920). 1955 Dec 31;35(6):649-60.

Therapeutic strategies in Sickle Cell Anemia: The past present and future.

Life Sci. 2017 Jun 1;178:100-108. doi: 10.1016/j.lfs.2017.03.025. Epub 2017 Apr 20.

Genetic Therapies for Sickle Cell Disease.

Pediatr Clin North Am. 2018 Jun;65(3):465-480. doi: 10.1016/j.pcl.2018.01.008.

Acceptability of prenatal diagnosis by a sample of parents of sickle cell anemia patients in Cameroon (sub-Saharan Africa).

J Genet Couns. 2011 Oct;20(5):476-85. doi: 10.1007/s10897-011-9372-y. Epub 2011 May 21.

Gene Therapy in a Patient with Sickle Cell Disease.

N Engl J Med. 2017 May 25;376(21):2093-4. doi: 10.1056/NEJMc1704009.

Gene Therapy in a Patient with Sickle Cell Disease.

N Engl J Med. 2017 May 25;376(21):2094. doi: 10.1056/NEJMc1704009.

Bone marrow transplantation (BMT) and gene replacement therapy (GRT) in sickle cell anemia.

Niger J Med. 2008 Jul-Aug;17(3):251-6. doi: 10.4314/njm.v17i3.37390.

Rounding up sickle cells with gene therapy.

Sci Transl Med. 2017 Mar 15;9(381). doi: 10.1126/scitranslmed.aam9864.

Gene therapy in sickle cell disease: Possible utility and impact.

Cleve Clin J Med. 2020 Jan;87(1):28-29. doi: 10.3949/ccjm.87a.19124. Epub 2020 Jan 2.

引用本文的文献

Balancing benefits and burdens: a systematic review on ethical and social dimensions of gene and cell therapies for hereditary blood diseases.

BMC Med Ethics. 2025 Mar 14;26(1):36. doi: 10.1186/s12910-025-01188-3.

CRISPR technology in human diseases.

MedComm (2020). 2024 Jul 29;5(8):e672. doi: 10.1002/mco2.672. eCollection 2024 Aug.

Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women.

Expert Rev Hematol. 2024 Aug;17(8):493-504. doi: 10.1080/17474086.2024.2372320. Epub 2024 Jun 26.

Life after sickle cell disease, is it really uhuru?

Lancet Haematol. 2023 Dec;10(12):e946-e949. doi: 10.1016/S2352-3026(23)00306-X.

A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America.

Pharmacoecon Open. 2023 Mar;7(2):313-320. doi: 10.1007/s41669-023-00390-6. Epub 2023 Feb 11.

Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study.

PLoS One. 2022 Nov 29;17(11):e0278137. doi: 10.1371/journal.pone.0278137. eCollection 2022.

Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance.

Blood Adv. 2023 Feb 14;7(3):365-374. doi: 10.1182/bloodadvances.2021006281.

A landscape analysis and discussion of value of gene therapies for sickle cell disease.

Expert Rev Pharmacoecon Outcomes Res. 2022 Sep;22(6):891-911. doi: 10.1080/14737167.2022.2060823. Epub 2022 Apr 18.

Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.

Mol Ther. 2021 Nov 3;29(11):3163-3178. doi: 10.1016/j.ymthe.2021.10.002. Epub 2021 Oct 8.